1.1
Lawson-Ayayi S, Cazanave C, Kpozehouen A, Barthe N, Mehsen N, Hessamfar M, Dupon M, Dabis F, Neau D; for the Groupe d’Epidémiologie Clinique du SIDA en Aquitaine (GECSA).
Chronic viral hepatitis is associated with low bone mineral density in HIV-infected patients, ANRS CO 3 Aquitaine Cohort.
J Acquir Immune Defic Syndr 2013;62(4):430-435.
1.2
Morlat P, Vivot A, Vandenhende MA, Dauchy FA, Asselineau J, Déti E, Gerard Y, Lazaro E, Duffau P, Neau D, Bonnet F, Chêne G; Groupe D’epidémiologie Clinique du Sida en Aquitaine (Gecsa).
Role of traditional risk factors and antiretroviral drugs in the incidence of chronic kidney disease, ANRS CO3 Aquitaine cohort, France, 2004-2012.
PLoS One 2013;8(6):e66223.
1.3
Bonnet F, Amieva H, Marquant F, Bernard C, Bruyand M, Dauchy FA, Mercié P, Greib C, Richert L, Neau D, Catheline G, Dehail P, Dabis F, Morlat P, Dartigues JF, Chêne G; for the ANRS CO3 Aquitaine Cohort.
Cognitive disorders in HIV-infected patients: are they HIV-related?
AIDS 2013;27(3):391-400.
1.4
Richert L, Brault M, Mercié P, Dauchy FA, Bruyand M, Greib C, Dabis F, Bonnet F, Chêne G, Dehail P and the Groupe d’Epidémiologie Clinique du SIDA en Aquitaine (GECSA).
Hand grip strength is only weakly correlated with physical function in well-controlled HIV infection, ANRS CO3 Aquitaine Cohort.
JAIDS, 2014 Jan 1;65(1):e25-7
1.5
Cazanave C, Lawson-Ayayi S, Hessamfar M, Neau D, Dupon M, Morlat P, Dabis F, de Barbeyrac B, Bébéar C, Pereyre S.
Prevalence of Mycoplasma genitalium among HIV-infected women, Agence Nationale de Recherches sur le SIDA et les hépatites virales CO3 Aquitaine Cohort, France.
Sex Transm Dis 2013;40(8):653-654.
1.6
Wittkop L, Bitard J, Lazaro E, Neau D, Bonnet F, Mercie P, Dupon M, Hessamfar M, Ventura M, Malvy D, Dabis F, Pellegrin JL, Moreau JF, Thiébaut R, Pellegrin I; for the Groupe d'Epidémiologie Clinique du SIDA en Aquitaine.
Effect of Cytomegalovirus-Induced Immune Response, Self Antigen–Induced Immune Response, and Microbial Translocation on Chronic Immune Activation in Successfully Treated HIV Type 1–Infected Patients: The ANRS CO3 Aquitaine Cohort.
J Infect Dis 2013;207(4): 622-627.
1.7
Carrieri MP, Lions C, Sogni P, Winnock M, Roux P, Mora M, Bonnard P, Salmon D, Dabis F, Spire B; the ANRS CO13 HEPAVIH Study Group.
Association between elevated coffee consumption and daily chocolate intake with normal liver enzymes in HIV-HCV infected individuals: Results from the ANRS CO13 HEPAVIH cohort study.
J Hepatol 2014 Jan;60(1):46-53.
1.8
Castera L, Winnock M, Pambrun E, Paradis V, Perez P, Loko MA, Asselineau J, Dabis F, Degos F, Salmon D.
Comparison of transient elastography (FibroScan), FibroTest, APRI and two algorithms combining these non-invasive tests for liver fibrosis staging in HIV/HCV coinfected patients: ANRS CO13 HEPAVIH and FIBROSTIC collaboration.
HIV Med 2014 Jan;15(1):30-9.
1.9
Marcellin F, Lions C, Winnock M, Salmon D, Durant J, Spire B, Mora M, Loko MA, Dabis F, Dominguez S, Roux P, Carrieri MP; ANRS CO13 HEPAVIH Study Group.
Self-reported alcohol abuse in HIV-HCV co-infected patients: a better predictor of HIV virological rebound than physician's perceptions (HEPAVIH ARNS CO13 cohort).
Addiction. 2013; 108(7):1250-1258.
1.10
Roux P, Lions C, Cohen J, Winnock M, Salmon-Céron D, Bani-Sadr F, Sogni P, Spire B, Dabis F, Carrieri MP; the ANRS CO 13 HEPAVIH Study Group.
Impact of HCV treatment and depressive symptoms on adherence to HAART among coinfected HIV-HCV patients: results from the ANRS-CO13-HEPAVIH cohort.
Antivir Ther 2013 in press.
1.11
Winnock M, Bani-Sadr F, Pambrun E, Loko MA, Carrieri P, Neau D, Morlat P, Marchou B, Dabis F, Salmon D, French National Agency for Research on AIDS and Viral Hepatitis (ANRS) CO13 HEPAVIH Study Group.
Factors associated with guideline-based hepatitis C virus (HCV) treatment initiation in HIV/HCV-coinfected patients: role of comorbidities and physicians' perceptions.
HIV Med 2013;14(7):430-436.
1.12
Antiretroviral Therapy Cohort Collaboration (ART-CC).
Durability of first ART regimen and risk factors for modification, interruption or death in HIV-positive patients starting ART in Europe and North America 2002-2009.
AIDS 2013;27(5):803-13.
1.13
Antiretroviral Therapy Cohort Collaboration (ART-CC), Shepherd BS, Jenkins CA, Parrish DD, Glass TR, Cescon A, Masabeu A, Chene G, de Wolf F, Crane HM, Jarrin I, Gill J, del Amo J, Abgrall S, Khaykin P, Lehmann C, Ingle SM, May MT, Sterne JA, Sterling TR.
Higher rates of AIDS during the first year of antiretroviral therapy among migrants: the importance of tuberculosis.
AIDS 2013;27(8):1321-1329.
1.14
Antiretroviral Therapy Cohort Collaboration (ART-CC).
Influence of geographical origin and ethnicity on mortality in patients on antiretroviral therapy in Canada, Europe, and the United States.
Clin Infect Dis 2013;56(12):1800-1809.
1.15
Grint D, Peters L, Reekie J, Soriano V, Kirk O, Knysz B, Suetnov O, Lazzarin A, Ledergerber B, Rockstroh JK, Mocroft A; EuroSIDA in EuroCoord (European Coordinating Committee for the Integration of Ongoing Coordination Actions Related to Clinical and Epidemiological HIV Research).
Stability of hepatitis C virus (HCV) RNA levels among interferon-naïve HIV/HCV-coinfected individuals treated with combination antiretroviral therapy.
HIV Med 2013;14(6):370-8.
1.16
Grint D, Peters L, Schwarze-Zander C, Beniowski M, Pradier C, Battegay M, Jevtovic D, Soriano V, Lundgren JD, Rockstroh JK, Kirk O, Mocroft A; EuroSIDA in EuroCoord.
Temporal changes and regional differences in treatment uptake of hepatitis C therapy in EuroSIDA.
HIV Med 2013;14(10):614-23.
1.17
Huang X, Lodi S, Fox Z, Li W, Phillips A, Porter K, Lutsar I, Kelleher A, Li N, Xu X, Wu H, Johnson AM; Beijing PRIMO cohort study; CASCADE Collaboration in EuroCoord.
Rate of CD4 decline and HIV-RNA change following HIV seroconversion in men who have sex with men: a comparison between the Beijing PRIMO and CASCADE cohorts.
J Acquir Immune Defic Syndr 2013; 62(4):441-6.
1.18
Kaulich-Bartz J, Dam W, May MT, Lederberger B, Widmer U, Phillips AN, Grabar S, Mocroft A, Vilaro J, van Sighem A, Moreno S, Dabis F, Monforte AD, Teira R, Ingle SM, Sterne JA; Writing Committee for the Antiretroviral Therapy Cohort Collaboration.
Insurability of HIV-positive people treated with antiretroviral therapy in Europe: collaborative analysis of HIV cohort studies.
AIDS 2013;27(10):1641-55.
1.19
Lodi S, del Amo J, d'Arminio Monforte A, Abgrall S, Sabin C, Morrison C, Furrer H, Muga R, Porter K, Girardi E; CASCADE collaboration in EuroCoord.
Risk of tuberculosis following HIV seroconversion in high-income countries.
Thorax 2013;68(3):207-13.
1.20
Madec Y, Boufassa F, Porter K, Prins M, Sabin C, d'Arminio Monforte A, Amornkul P, Bartmeyer B, Sannes M, Venet A, Lambotte O, Meyer L; CASCADE Collaboration in Eurocoord.
Natural history of HIV-control since seroconversion.
AIDS 2013;27(15):2451-60.
1.21
May MT, Ingle SM, Costagliola D, Justice AC, de Wolf F, Cavassini M, D'Arminio Monforte A, Casabona J, Hogg RS, Mocroft A, Lampe FC, Dabis F, Fätkenheuer G, Sterling TR, Del Amo J, Gill MJ, Crane HM, Saag MS, Guest J, Brodt HR, Sterne JA; the Antiretroviral Cohort Collaboration.
Cohort profile: Antiretroviral Therapy Cohort Collaboration (ART-CC).
Int J Epidemiol 2013 [Epub].
1.22
Mocroft A, Phillips AN, Gatell J, Horban A, Ledergerber B, Zilmer K, Jevtovic D, Maltez F, Podlekareva D, Lundgren JD; EuroSIDA study in EuroCOORD.
CD4 cell count and viral load-specific rates of AIDS, non-AIDS and deaths according to current antiretroviral use.
AIDS 2013;27(6):907-918.
1.23
Mocroft A, Furrer HJ, Miro JM, Reiss P, Mussini C, Kirk O, Abgrall S, Ayayi S , Bartmeyer B, Braun D, Castagna A, d'Arminio Monforte A, Gazzard B, Gutierrez F, Hurtado I, Jansen K, Meyer L, Muñoz P, Obel N, Soler-Palacin P, Papadopoulos A, Raffi F, Ramos JT, Rockstroh JK, Salmon D, Torti C, Warszawski J, de Wit S, Zangerle R, Fabre-Colin C, Kjaer J, Chêne G , Grarup J, Lundgren JD; Opportunistic Infections Working Group on behalf of the Collaboration of Observational HIV Epidemiological Research Europe (COHERE) study in EuroCOORD.
The incidence of AIDS-defining illnesses at a current CD4 count ≥ 200 cells/μL in the post-combination antiretroviral therapy era.
Clin Infect Dis 2013;57(7):1038-47.
1.24
Mocroft A, Lundgren JD, Sabin ML, Monforte Ad, Brockmeyer N, Casabona J, Castagna A, Costagliola D, Dabis F, De Wit S, Fätkenheuer G, Furrer H, Johnson AM, Lazanas MK, Leport C, Moreno S, Obel N, Post FA, Reekie J, Reiss P, Sabin C, Skaletz-Rorowski A, Suarez-Lozano I, Torti C, Warszawski J, Zangerle R, Fabre-Colin C, Kjaer J, Chene G, Grarup J, Kirk O; Collaboration of Observational HIV Epidemiological Research Europe (COHERE) study in EuroCoord.
Risk Factors and Outcomes for Late Presentation for HIV-Positive Persons in Europe: Results from the Collaboration of Observational HIV Epidemiological Research Europe Study (COHERE).
PLoS Med 2013;10(9):e1001510.
1.25
Monforte Ad, Reiss P, Ryom L, El-Sadr W, Dabis F, De Wit S, Worm SW, Law MG, Weber R, Kirk O, Pradier C, Phillips AN, Lundgren JD, Sabin CA.
Atazanavir is not associated with an increased risk of cardio- or cerebrovascular disease events.
AIDS 2013; 27(3):407-415.
1.26
Peters L, Mocroft A, Soriano V, Rockstroh J, Rauch A, Karlsson A, Knysz B, Pradier C, Zilmer K, Lundgren JD; for EuroSIDA in EuroCoord. Hyaluronic acid levels predict risk of hepatic encephalopathy and liver-related death in HIV/viral hepatitis coinfected patients. PLoS One 2013;8(5):e64283.
1.27
Podlekareva DN, Panteleev AM, Grint D, Post FA, Miro JM, Bruyand M, Furrer H, Obel N, Girardi E, Vasilenko A, Losso MH, Arenas-Pinto A, Caylá J, Rakhmanova A, Zeltina I, Werlinrud AM, Lundgren JD, Mocroft A, Kirk O; the HIV/TB study group.
Short and long term mortality and causes of death in HIV/TB patients in Europe.
Eur Respir J 2014 Jan;43(1):166-77.
1.28
Podlekareva DN, Grint D, Post FA, Mocroft A, Panteleev AM, Miller RF, Miro JM, Bruyand M, Furrer H, Riekstina V, Girardi E, Losso MH, Caylá JA, Malashenkov EA, Obel N, Skrahina AM, Lundgren JD, Kirk O; HIV-TB Study Group.
Health care index score and risk of death following tuberculosis diagnosis in HIV-positive patients.
Int J Tuberc Lung Dis 2013;17(2):198-206.
1.29
Pursuing Later Treatment Option II (PLATO II) Project Team of the Collaboration of Observational HIV Epidemiological Research Europe (COHERE), Costagliola D, Ledergerber B, Torti C, van Sighem A, Podzamczer D, Mocroft A, Dorrucci M, Masquelier B, de Luca A, Jansen K, De Wit S, Obel N, Fätkenheuer G, Touloumi G, Mussini C, Castagna A, Stephan C, García F, Zangerle R, Duval X, Perez-Hoyos S, Meyer L, Ghosn J, Fabre-Colin C, Kjaer J, Chêne G, Grarup J, Phillips A, Lodwick R, Torti C, Dorrucci M, Günthard HF, Michalik C, Chrysos G, Castagna A.
Predictors of CD4(+) T-cell counts of HIV type 1-infected persons after virologic failure of all 3 original antiretroviral drug classes.
J Infect Dis 2013;207(5):759-67.
1.30
Rockstroh JK, Peters L, Grint D, Soriano V, Reiss P, Monforte Ad, Beniowski M, Losso MH, Kirk O, Kupfer B, Mocroft A; EuroSIDA in EuroCoord.
Does hepatitis C viremia or genotype predict the risk of mortality in individuals co-infected with HIV?
J Hepatol 2013;59(2):213-20.
1.31
Rosińska M, Marzec-Bogustawska A, Janiec J, Smoleń-Dzirba J, Wąsik T, Gniewosz J, Zalewska M, Murphy G, McKinney E, Porter K; CASCADE Collaboration In Eurocoord.
High percentage of recent HIV infection among HIV-positive individuals newly diagnosed at voluntary counseling and testing sites in Poland.
AIDS Res Hum Retroviruses 2013;29(5):805-813.
1.32
Ryom L, Kirk O, Lundgren JD, Reiss P, Pedersen C, De Wit S, Buzunova S, Gasiorowski J, Gatell JM, Mocroft A; EuroSIDA in EuroCoord.
Advanced chronic kidney disease, end-stage renal disease and renal death among HIV-positive individuals in Europe.
HIV Med 2013;14(8):503-508.
1.33
Ryom L, Mocroft A, Kirk O, Worm SW, Kamara DA, Reiss P, Ross M, Fux CA, Morlat P, Moranne O, Smith C, Lundgren JD; D:A:D Study Group.
Association between antiretroviral exposure and renal impairment among HIV-positive persons with normal baseline renal function: the D:A:D study.
J Infect Dis 2013;207(9):1359-1369.
1.34
Sabin CA, Ryom L, Kovari H, Kirk O, de Wit S, Law M, Reiss P, Dabis F, Pradier C, El-Sadr W, Monforte Ad, Kamara D, Phillips AN, Lundgren JD.
Association between ALT level and the rate of cardio/cerebrovascular events in HIV-positive individuals: the D: A: D study.
J Acquir Immune Defic Syndr 2013;63(4):456-463.
1.35
Søgaard OS, Reekie J, Ristola M, Jevtovic D, Karpov I, Beniowski M, Servitskiy S, Domingo P, Reiss P, Mocroft A, Kirk O.
Severe bacterial non-aids infections in HIV-positive persons: incidence rates and risk factors.
Infect 2013; 66(5):439-446.
1.36
Touloumi G, Pantazis N, Pillay D, Paraskevis D, Chaix ML, Bucher HC, Kücherer C, Zangerle R, Kran AM, Porter K; CASCADE collaboration in EuroCoord.
Impact of HIV-1 subtype on CD4 count at HIV seroconversion, rate of decline, and viral load set point in European seroconverter cohorts.
Clin Infect Dis 2013;56(6):888-897.
1.37
Touloumi G, Pantazis N, Chaix ML, Bucher HC, Zangerle R, Kran AM, Thiebaut R, Masquelier B, Kucherer C, Monforte Ad, Meyer L, Porter K; for CASCADE Collaboration in EuroCoord.
Virologic and immunologic response to cART by HIV-1 subtype in the CASCADE collaboration.
PLoS One 2013; 8(7):e71174.
1.38
Van Der Helm J, Geskus R, Sabin C, Meyer L, Del Amo J, Chêne G , Dorrucci M, Muga R, Porter K, Prins M; CASCADE Collaboration in EuroCoord.
Effect of HCV infection on cause-specific mortality after HIV seroconversion, before and after 1997.
Gastroenterology 2013;144(4):751-760.
1.39
Worm SW, Bower M, Reiss P, Bonnet F, Law M, Fätkenheuer G, d'Arminio Monforte A, Abrams DI, Grulich A, Fontas E, Kirk O, Furrer H, Wit SD, Phillips A, Lundgren JD, Sabin CA; D:A:D Study Group.
Non-AIDS defining cancers in the D:A:D Study - time trends and predictors of survival: a cohort study.
BMC Infect Dis 2013;13:471.
2.1
Carrieri MP, Lions C, Sogni P, Winnock M, Roux P, Mora M, Bonnard P, Salmon D , Dabis F, Spire B.
Association between elevated coffee consumption and daily chocolate intake with normal liver enzymes in HIV HCV infected individuals : results from the ANRS CO13 HEPAVIH cohort study.
11th International AIDS Impact Conference. September 29-October 2nd, 2013, Barcelona, Spain [Oral Abstract].
2.2
Dabis F, Delaune J, Merchadou L, Loko MA, Winnock M, Poizot-Martin I, Salmon D for the ANRS CO13 HEPAVIH study group.
Early results on safety and efficacy of HCV tritherapy with telaprevir or boceprevir in real life setting – ANRS CO13 HEPAVIH cohort of HIV HCV co infected patients (France)
17th International Workshop on HIV Observational Databases, 11-13 April 2013, Cavtat, Croatia [Poster Abstract].
2.3
Henard S, Roussillon C, Bonnet F, Taieb A, Cacoub P, Salmon D, Rosenthal E, Morlat P, Chêne G, and May T Cardiovascular-related Deaths in HIV+ Patients between 2000 and 2010: Agence Nationale de Recherche sur le Sida EN20 Mortalité 2010 Survey.
20th Conference on Retroviruses and Opportunistic Infections, 3-6 March 2013, Atlanta (USA) [Poster Abstract 1048].
2.4
Marcellin M, Cohen J, Salmon D, Winnock M, Dabis F, Loko MA, Garipuy D, Bouchaud O, Spire B, Carrieri MC, Roux P for the HEPAVIH ANRS CO13 cohort.
Addictive behaviors and hepatitis C virus (HCV) clearance following treatment. Exploratory study among HIV HCV coinfected patients (ANRS CO13 HEPAVIH);
11th International AIDS Impact Conference, September 29-October 2nd, 2013, Barcelona, Spain [Oral Abstract].
2.5
Miaihles P, Lacombe K, E Arends J, Puoti M, Rosenthal E, Morlat M, Dominguez S, Valantin MA, Gilbert C, Winnock M, Dabis F, Rockstroh J, Salmon D and the ANRS CO13 HEPAVIH cohort, and ESCMID European study group on viral hepatitis.
Triple therapy with telaprevir (TPV) or boceprevir (BOC) in cirrhotic HIV/HCV infected patients: real life on-treatment data from Europe.
Comorbidities and Advers Drug Reactions in HIV. 15-17 October 2013, Brussels [Oral Abstract].
2.6
Nasta P, Salmon D, D’Arminio Monforte A, Pimenta J, Cerini C, E Chiari, Winnock M, Cozzi Lepri A. Fosamprenavir/Ritonavir (FPV/r) in hepatically impaired subjects : an observational multi-cohort study.
53rd Interscience Conference on Antimicrobial Agents and Chemotherapy, September 10-13, 2013, Denver Colorado, USA [Poster 1529].
2.7
Poizot Martin I, Gilbert C, Carrieri MP, Miailhes P, Billaud E, Dominguez S, Dabis F, Sogni P, Loko MA, Salmon D.
Access to HCV triple therapy with telaprevir or boceprevir in real-life setting in HIV HCV coinfected patients. ANRS CO13 HEPAVIH Cohort (France).
7th IAS Conference on HIV Pathogenesis, Treatment and Prevention (IAS 2013), 30 June-3 July 2013, Kuala Lumpur, Malaysia [Oral Abstract].
2.8
Borges AH, Lundgren JD, Kirk O, Ridolfo A, Katlama C, Antunes F, Grzeszczuk A, Blaxhult A, Mitsura VM and Mocroft A on behalf of EuroSIDA in EuroCOORD Development of thrombocytopenia and risk of AIDS and serious non-AIDS events in Europe.
14th European AIDS Conference, 16-19 October 2013, Brussels, Belgium [Poster No. PE 12/11].
2.9
Boulle A, Schomaker M, May M, Egger M, Sterne J, and site investigators from IeDEA-SA and ART-CC Collaborations.
Mortality after Starting ART in Treatment-naïve Adults in 3 Continents: Collaborative Analysis of International Epidemiologic Databases to Evaluate AIDS in Southern Africa and ART Cohort Collaboration Cohorts.
20th Conference on Retroviruses and Opportunistic Infections, 3-6 March 2013, Atlanta (USA) [Oral Abstract 150].
2.10
Bruyand M, Ryom L, Shepherd L, Reiss P, de Wit S, d’Arminio Monforte A, Rickenbach M, Phillips A, Lundgren J, Sabin C, and D:A:D Study Group.
Cancer Risk and Use of Protease Inhibitor- or NNRTI-based cART: The D:A:D Study.
20th Conference on Retroviruses and Opportunistic Infections, 3-6 March 2013, Atlanta (USA) [Poster Abstract 742b].
2.11
Casadellà M, Cozzi-Lepri A, Phillips A, Noguera-Julian M, Bickel M, Duiculescu D, Zilmer K, Clotet B, Lundgren JD, Paredes R for EuroSIDA in EuroCOORD.
Detection of Non-R5 HIV-1 by Ultrasensitive Genotypic Testing Is Associated with CD4+ Count Decreases Also After the Initiation of ART.
11th European Meeting on HIV & Hepatitis, 20-22 March 2013, Rome, Italy [Oral abstract O_24].
2.12
Cozzi-Lepri A, Phillips AN, Paredes R, Jablonowska E, Florence E, Pedersen C, Staub T, Ledergerber B, Mocroft A and Lundgren J, for EuroSIDA in EuroCoord.
Estimation of percentage of HIV-infected people with limited future drug options in a closed observational setting over the period 2007-2011 and beyond.
14th European AIDS Conference, 16-19 October 2013, Brussels, Belgium [Poster No. PE 9/12].
2.13
Del Amo J for the socio-economic inequalities working group of COHERE in EuroCoord.
Response to combination antiretroviral treatment in HIV-positive individuals in Europe: variation by educational level.
14th European AIDS Conference, 16-19 October 2013, Brussels, Belgium [Oral presentation].
2.14
Friis Møller N, Ryom L, Smith C, Weber R, Reiss P, Dabis F, De Wit S, D´Arminio Monforte A, Kirk O, Fontas E, Sabin C, Phillips A, Lundgren J, Law M for the D:A:D Study group.
Prediction of global CVD risk in HIV-positive persons.
14th European AIDS Conference, 16-19 October 2013, Brussels, Belgium [Oral presentation].
2.15
Grint D, Peters L, Rockstroh J, Lundgren J, De Wit S, Mitsura V, Kynsz B, Pedersen C, Kirk O, Mocroft A, and EuroSIDA.
Increased Risk of ARV Drug Discontinuation among Patients with High Hyaluronic Acid, a Marker of Liver Fibrosis.
20th Conference on Retroviruses and Opportunistic Infections, 3-6 March 2013, Atlanta (USA) [Poster Abstract 641].
2.16
Grint D, Podlekareva D, Karpov I, Rakmanova A, Chentsova N, Lundgren J D, Mocroft A, Kirk O for EuroSIDA in EuroCoord.
Is Stavudine (D4T) still being used in EuroSIDA despite its association with toxicity and a higher frequency of sever adverse events?
14th European AIDS Conference, 16-19 October 2013, Brussels, Belgium [Poster No. PE PE8/5].
2.17
Ingle S, Glass T, Crane H, Hogg R, Gill J, Ammassari A, Mugavero M, Tate J, Turner N, Sterne J, and ART Cohort Collaboration.
Associations of Self-reported and Prescription-based Adherence with Viral Suppression in 5 HIV Cohort Studies.
20th Conference on Retroviruses and Opportunistic Infections, 3-6 March 2013, Atlanta (USA) [Poster Abstract 583].
2.18
Kirk O, Reiss P, Rakhmanova A, Benhegyi D, Phillips AN, De Wit S, Ristola M, Lundgren JD, Grarup J, Mocroft A, for EuroSIDA in EuroCoord
A survey of ATRIPLA use in clinical practice among treatment-naïve HIV-positive patients in Europe.
14th European AIDS Conference, 16-19 October 2013, Brussels, Belgium [Poster No. PE8/38].
2.19
Lodi S on behalf of COHERE in EuroCoord. Late HIV diagnosis, late initiation of combination ART and mortality in Europe: variation by educations level.
7th IAS Conference on HIV Pathogenesis, Treatment and Prevention (IAS 2013), 30 June-3 July 2013, Kuala Lumpur, Malaysia [ Poster].
2.20
Mansfeld M, Skrahina A, Panteleev AM, Miro JM, Zeltina I, Tetradov S, Mocroft A, Furrer H, Grzeszczuk A, Shepherd L, Bolokadze N, Lundgren JD, Matteelli A, Post FA, Kirk O, Podlekareva DN, and the TB:HIV study in EuroCoord.
Organisation and delivery of healthcare for HIV/TB coinfected patients in Europe.
14th European AIDS Conference, 16-19 October 2013, Brussels, Belgium [Oral presentation].
2.21
Marzolini C on behalf of the obesity working group of COHERE in EuroCoord.
Obese HIV-infected patients treated with efavirenz-containing regimens are at risk of virological failure.
14th European AIDS Conference, 16-19 October 2013, Brussels, Belgium [Oral presentation]
2.22
May M, Gill M, Harrigan R, Klein M, Reiss P, Mocroft A, d’Arminio Monforte A, Zangerle R, Cavassini M, Sterne J, and ART Cohort Collaboration.
Mortality of Treated HIV-1+ Individuals according to Viral Subtype in Europe and Canada: ART Cohort Collaboration
20th Conference on Retroviruses and Opportunistic Infections, 3-6 March 2013, Atlanta (USA) [Poster Abstract 577].
2.23
May M, Mocroft A, Guest J, Crane H, Reiss P, d’Arminio Monforte A, Labarga P, Wasmuth J-C, Ingle S, Hogg R, and ART Cohort Collaboration
Contribution of AIDS and Non-AIDS Deaths to Lower Life Expectancy of ART-treated HIV+ Individuals Compared with the General Population
20th Conference on Retroviruses and Opportunistic Infections, 3-6 March 2013, Atlanta, (USA) [Poster Abstract 568].
2.24
Mocroft A and COHERE in EuroCOORD The Incidence and Risk of AIDS-defining Illnesses at Current CD4 Counts of 500/mm3 or Higher.
20th Conference on Retroviruses and Opportunistic Infections, 3-6 March 2013, Atlanta, (USA) [Poster Abstract 1041].
2.25
Mocroft A, Ryom L, Reiss P, Ledergerber B, d’Arminio Monforte A, Gatell J, de Wit S, Beniowski M, Lundgren J, Kirk O, and EuroSIDA in EuroCOORD.
A Comparison of Estimated Glomerular Filtration Rates Using Cockcroft-Gault and the Chronic Kidney Disease Epidemiology Collaboration Estimating Equations.
20th Conference on Retroviruses and Opportunistic Infections, 3-6 March 2013, Atlanta (USA) [Poster Abstract 808].
2.26
Mocroft A on behalf of EuroSIDA in EuroCoord. The spectrum of clinical disease and relationship with measures of deteriorating renal function.
14th European AIDS Conference, 16-19 October 2013, Brussels, Belgium [Oral presentation].
2.27
Monge S on behalf of the migrants working group of COHERE in EuroCoord.
Mortality in migrants living with HIV in Western European countries: differences by geographical origin and gender.
14th European AIDS Conference, 16-19 October 2013, Brussels, Belgium [Oral presentation].
2.28
Noguera-Julian M, Cozzi-Lepri, Di Giallonardo F, Schuurman R, Däumer M, Aitken S, Günthard HF, Brun-Vezinet F, Metzner KJ, Paredes R, and Chain minority HIV-1 variants working Group.
Drug Resistance Surveillance by Ultrasensitive Genotyping in People Starting First Line NNRTI-based Regimens in Europe.
18th International Bioinformatics Workshop on Virus Evolution and Molecular Epidemiology, 25- August 30 2013, Gainesville, Florida, USA, [Poster Abstract].
2.29
Olson A, Touloumi G, Geskus R, Meyer L, Prins M, Chêne G, De Luca A, Costagliola D, Porter K, and CASCADE Collaboration in EuroCoord.
Mean Asymptomatic Viral Load, Steady State Viral Load, and CD4 Cell Count following Acute Infection as Predictors of HIV Disease Progression
20th Conference on Retroviruses and Opportunistic Infections, 3-6 March 2013, Atlanta (USA) [Poster Abstract 268].
2.30
Petoumenos K, El-Sadr W, d’Arminio Monforte A, Sabin C, Reiss P, Ryom L, De Wit S, Rickenbach M, Lundgren J, Law M, for D:A:D Study Group Increased Risk of Cardiovascular Disease with Age in Men: A Comparison of D:A:D with HIV– Cardiovascular Disease Risk Equations.
20th Conference on Retroviruses and Opportunistic Infections, 3-6 March 2013, Atlanta (USA) [Oral Abstract 61]
2.31
Ryom L, Mocroft A, Kirk O, El-Sadr W, Ross M, Reiss P, De Wit S, Morlat P, Fux C, Lundgren J, and D:A:D Study Group Predictors of Advanced Chronic Kidney Disease and End-stage Renal Disease in HIV+ Persons: D:A:D.
20th Conference on Retroviruses and Opportunistic Infections, 3-6 March 2013, Atlanta (USA) [Poster Abstract 810].
2.32
Sabin S, Ryom L, Law M, El-Sadr W, Kirk O, Bruyand M, Reiss P, Pradier C, Ledergerber B, Lundgren J, and D:A:D Study.
Improvements in Short-term Mortality following Myocardial Infarction: The Data Collection on Adverse events of Anti-HIV Drugs Study
20th Conference on Retroviruses and Opportunistic Infections, 3-6 March 2013, Atlanta (USA) [Poster Abstract 748]
2.33
Schultze A on behalf of EuroSIDA in EuroCoord. Prevalence of detected drug resistance across different regions of Europe: Data from EuroSIDA 1997-2012.
14th European AIDS Conference, 16-19 October 2013, Brussels, Belgium [Oral presentation].
2.34
Shahmanesh M on behalf of EuroSIDA in EuroCoord Management of cardiovascular risk in HIV positive individuals in Europe.
14th European AIDS Conference, 16-19 October 2013, Brussels, Belgium [Oral presentation].
2.35
Shepherd L on behalf of EuroSIDA in EuroCoord. Infection related and unrelated malignancies, HIV and the aging population.
14th European AIDS Conference, 16-19 October 2013, Brussels, Belgium [Oral presentation].
2.36
Smith CJ, Ford D, Hernan M, Sabin CA, Reiss P, de Wit S, d’Arminio Monforte A, Pradier C, Law M, Fontas E, Weber R, Bruyand M, El-Sadr W, Phillips A, Ryom L, Lundgren JD for the D:A:D Study Group.
Investigating the causal impact of PI- and NNRTI-containing cART on the risk of mortality: methodological challenges.
14th European AIDS Conference, 16-19 October 2013, Brussels, Belgium [Poster No. PE8/12]
2.37
Viard JP on behalf of EuroSIDA in EuroCoord.
Prognostic value of vitamin D level for all-cause mortality, and association with inflammatory markers in HIV-infected persons.
14th European AIDS Conference, 16-19 October 2013, Brussels, Belgium [Oral presentation ].
2.38
Wittkop L on behalf of EuroCoord-CHAIN Subtype Project Team
Effect of HIV-1 Subtypes on Virological and Immunological Response to Initial cART: A European Multicohort Study.
20th Conference on Retroviruses and Opportunistic Infections, 3-6 March 2013, Atlanta (USA) [Poster Abstract 572].